Objective: To assess the practical utility of pleural fluid carbonic anhydrase XII (CAXII) quantification fordifferential diagnosis of effusions. Materials and Methods: Fluid was collected prospectively from fifty patientspresenting with lymphocytic pleural effusions for investigation and CAXII was quantified by ELISA. Results:Pleural fluid CAXII concentrations were significantly higher in lung cancer patients (n=30) than in tuberculouscontrols (n=20). The sensitivity and specificity of this biomarker were 60%and 75%, respectively. CAXIImeasurement was not inferior to cytological examination in the diagnosis and exclusion of pleural effusionsfrom lung cancer patitents (sensitivity 60% vs. 57%; specificity 75% vs. 100%; positive predictive value 77%;negative predictive value 54%). In patients with negative cytology, it offered a sensitivity of 54%. Conclusions:Pleural fluid CAXII is elevated in pleural effusions from lung cancer patients. Measurement of CAXII may beused in the future as a valuable adjunct to cytology in the diagnostic assessment of patients with pleural effusionsrelated to lung cancer, especially when cytological examination is inconclusive.
(2013). Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions. Asian Pacific Journal of Cancer Prevention, 14(1), 351-354.
MLA
. "Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions". Asian Pacific Journal of Cancer Prevention, 14, 1, 2013, 351-354.
HARVARD
(2013). 'Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions', Asian Pacific Journal of Cancer Prevention, 14(1), pp. 351-354.
VANCOUVER
Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions. Asian Pacific Journal of Cancer Prevention, 2013; 14(1): 351-354.